Leerink Partners Issues Positive Forecast for McKesson (NYSE:MCK) Stock Price

McKesson (NYSE:MCK) had its price target hoisted by analysts at Leerink Partners from $1,070.00 to $1,200.00 in a research report issued on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Leerink Partners‘s price target would suggest a potential upside of 10.80% from the company’s previous close.

A number of other research analysts have also recently commented on MCK. Evercore reiterated an “outperform” rating and set a $950.00 price target (down from $1,000.00) on shares of McKesson in a research report on Thursday, August 6th. Mizuho upped their price objective on shares of McKesson from $905.00 to $1,020.00 and gave the company a “neutral” rating in a research note on Tuesday, October 20th. Citigroup increased their target price on shares of McKesson from $945.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, July 24th. UBS Group lifted their target price on shares of McKesson from $1,080.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Friday, October 16th. Finally, Morgan Stanley set a $977.00 price target on shares of McKesson in a research note on Tuesday, October 6th. Fifteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $1,011.82.

McKesson Trading Up 1.3%

MCK traded up $13.57 on Thursday, reaching $1,083.01. The stock had a trading volume of 822,047 shares, compared to its average volume of 917,825. McKesson has a fifty-two week low of $723.68 and a fifty-two week high of $1,121.50. The firm has a 50-day moving average of $931.17 and a 200-day moving average of $865.74. The company has a market capitalization of $126.27 billion, a price-to-earnings ratio of 28.98, a price-to-earnings-growth ratio of 1.99 and a beta of 0.27.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $11.68 EPS for the quarter, topping analysts’ consensus estimates of $10.72 by $0.96. The company had revenue of $110.96 billion for the quarter, compared to analyst estimates of $109.90 billion. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. McKesson’s revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $9.86 earnings per share. Sell-side analysts anticipate that McKesson will post 44.71 EPS for the current fiscal year.

Insider Buying and Selling at McKesson

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 111 shares of the business’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total value of $98,950.95. Following the sale, the chief accounting officer directly owned 521 shares of the company’s stock, valued at approximately $464,445.45. The trade was a 17.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bradley E. Lerman sold 301 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $892.33, for a total transaction of $268,591.33. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 1,212 shares of company stock valued at $1,164,182. 0.06% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On McKesson

Several hedge funds and other institutional investors have recently bought and sold shares of MCK. BlackRock Inc. acquired a new stake in shares of McKesson in the second quarter worth approximately $8,156,743,000. Bank of America Corp DE raised its stake in McKesson by 2.4% in the 1st quarter. Bank of America Corp DE now owns 1,538,726 shares of the company’s stock valued at $1,331,552,000 after purchasing an additional 35,916 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in McKesson by 3.3% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 922,573 shares of the company’s stock valued at $697,096,000 after purchasing an additional 29,747 shares in the last quarter. Legal & General Group Plc purchased a new position in McKesson in the 2nd quarter valued at $656,566,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in McKesson during the 2nd quarter worth $651,462,000. Institutional investors own 85.07% of the company’s stock.

McKesson News Roundup

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson reported adjusted EPS of $11.68, ahead of analysts’ roughly $10.70–$10.72 estimates, while revenue of $110.96 billion topped expectations of $109.9 billion and grew about 7.5% year over year. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: The company raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40. Management cited specialty distribution, higher prescription volumes and GLP-1 momentum as growth drivers. McKesson Corp (MCK) Q2 2027 Earnings Call Highlights
• Positive Sentiment: TD Cowen and Evercore ISI each raised their price target to $1,200, from $1,006 and $1,000, respectively—signaling improved analyst expectations after the results. TD Cowen Adjusts Price Target Evercore ISI Adjusts Price Target
• Neutral Sentiment: McKesson closed its $2.25 billion Precision Medicine Group acquisition, expanding its position in precision medicine. The deal offers growth potential, with execution and integration still to come. McKesson Outlook and Precision Medicine Deal
• Negative Sentiment: Some investors appeared cautious despite the earnings beat, with reports describing an after-hours stock dip. Earlier coverage also flagged branded-drug pricing pressure as a potential headwind. Q2 Earnings and Outlook

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.